This trend is expected to continue, as the monoclonal antibody Gosuranemab, aimed at the N-terminal tau protein in patients with early-stage AD, failed to exhibit significant results in cognitive and functional assessments [5]. This evidence concerns the gene MAPT and Alzheimer disease.